Literature DB >> 21110841

Liver metastasis originating from colorectal cancer with macroscopic portal vein tumor thrombosis: a case report and review of the literature.

Yoshito Tomimaru1, Yo Sasaki, Terumasa Yamada, Kunihito Gotoh, Shingo Noura, Hidetoshi Eguchi, Isao Miyashiro, Masayuki Ohue, Hiroaki Ohigashi, Masahiko Yano, Osamu Ishikawa, Shingi Imaoka.   

Abstract

INTRODUCTION: Macroscopic tumor thrombi occupying the main portal branch are rarely seen in patients with liver metastasis. CASE
PRESENTATION: A 55-year-old Japanese man who had previously undergone surgery for adenocarcinoma of the ascending colon presented with a metastatic liver tumor accompanied by a macroscopic tumor thrombus in the right portal branch. Right lobectomy and removal of the tumor thrombus were performed, and the liver metastasis and tumor thrombus were successfully resected. Histopathological examination of the liver tumor revealed adenocarcinoma, consistent with that of the previous colon cancer, confirming that the liver tumor was a metastasis from the colon cancer. Our patient remains well without recurrence at 51 months after the liver surgery.
CONCLUSION: The prognosis of patients with liver metastasis accompanied by a portal vein tumor thrombus remains unknown, but, considering several previous reported cases together with our case report, a better prognosis may be expected if the tumor is successfully removed by anatomical liver resection.

Entities:  

Year:  2010        PMID: 21110841      PMCID: PMC3009980          DOI: 10.1186/1752-1947-4-382

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


Introduction

Portal vein tumor thrombosis (PVTT) is associated with hepatocellular carcinoma (HCC), with a reported incidence of PVTT of 30% to 70% [1-3]. A recent pathological study of metastatic liver cancer originating from colorectal cancer found microscopic tumor invasion in the intra-hepatic portal vein to be a relatively common finding in addition to HCC [4,5]. However, macroscopic tumor thrombi occupying the main portal branch are rare in patients with liver metastasis [6,7], including that from colorectal cancer (Table 1) [8-14].
Table 1

Previously reported cases with macroscopic portal vein thrombus (PVTT) from successfully resected colorectal cancers

Case no.ReferenceAge and genderSynchronous or metachronousLocation of primary tumorHistologyStageInterval from colorectal resection to diagnosis of PVTT, monthsSize of liver metastasis, mmLocation of liver metastasisLocation of PVTTSurvival after removal of PVTT, monthsPrognosis
1Tanaka et al. [8]59/MSynchronousSigmoidModT3N1-UnknownS8, leftLeft PV11Alive, recurrence
2Tanaka et al. [8]54/MMetachronousRectumModT4N21270S2/3Left PV21Alive, no recurrence
3Tanaka et al. [8]60/MMetachronousTransversePoorT3N2425S7Right PV31Alive, no recurrence
4Tanaka et al. [8]63/FMetachronousSigmoidWellT3N04755S6Posterior PV55Alive, no recurrence
5Tanaka et al. [8]62/FMetachronousDescendingModT3N111--Right PV102Alive, no recurrence
6Lee et al. [10]28/MSynchronousSigmoidMucUnknown (N+)-40S2/3Left PV branch1.5Alive, recurrence
7Sugiura et al. [11]39/FMetachronousTransverse, rectumWellUnknown141Unknown (huge)S4/5/6/7/8Left PV24Alive, no recurrence
8Urahashi et al. [12]57/MMetachronousTransverseModT3N1< 2440S6/7Main PV11Died, recurrence
9Urahashi et al. [12]51/MMetachronousTransverseModT3N2< 24145S7/8Anterior PV9Died, recurrence
10Urahashi et al. [12]54/MMetachronousRectumWellT3N2< 2435S3Left PV36Died, recurrence
11Urahashi et al. [12]70/FMetachronousAscendingModT3N1< 24--Main PV6Died, recurrence
12Urahashi et al. [12]45/FMetachronousDescendingModT3N2< 2460S5, S6, S8Main PV10Died, recurrence
13Oikawa et al. [13]55/FSynchronousRectosigmoidMucT3N1-100S6/7, leftPosterior PV9Died, recurrence
14Matsumoto et al. [14]58/MMetachronousRectosigmoidModT3N06--Left PV66Alive, no recurrence
15Present case55/FMetachronousAscendingModT4N11328S8Right PV51Alive, no recurrence

Mod = moderately differentiated adenocarcinoma; poor = poorly differentiated adenocarcinoma; PV = portal vein; PVTT = portal vein tumor thrombosis; well = well differentiated adenocarcinoma; muc = mucinous adenocarcinoma.

Previously reported cases with macroscopic portal vein thrombus (PVTT) from successfully resected colorectal cancers Mod = moderately differentiated adenocarcinoma; poor = poorly differentiated adenocarcinoma; PV = portal vein; PVTT = portal vein tumor thrombosis; well = well differentiated adenocarcinoma; muc = mucinous adenocarcinoma. We report on a case of liver metastasis from colon cancer with macroscopic tumor thrombi in the right portal branch. Herein, we describe the case and review the literature for liver metastases from colorectal cancer accompanied by macroscopic portal vein tumor thrombi.

Case presentation

A 55-year-old Japanese man underwent a right hemicolectomy in our hospital for a tumor in the ascending colon.. He did not have any inherited or acquired thrombophilic predispositions. The tumor was histopathologically diagnosed as moderately differentiated adenocarcinoma, and staged as IIIB (T4N1M0), according to the TNM (tumor, nodes, metastasis) classification [15]. Tumor markers including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were all within normal limits before the operation. During follow-up in our outpatient clinic, our patient received adjuvant systemic chemotherapy for six months. Despite the adjuvant treatment, abdominal computed tomography (CT) 13 months after surgery showed a liver tumor in segment 8 based on Couinaud's classification [16]. Our patient was subsequently readmitted to our hospital for full diagnosis and treatment of the liver tumor. Hepatitis B surface antigen, hepatitis B core antibody, and hepatitis C antibody test results were negative. Tumor markers including CEA, CA19-9, α-fetoprotein, and protein induced by vitamin K absence or antagonist II, were all within normal limits. CT arteriography (CTA) showed a tumor of approximately 25 mm in diameter consisting of two components: an apparently solid part and a cystic component. The solid component of the tumor was enhanced in the early phase of the CTA and was washed out in the delayed phase, a pattern compatible with HCC (Figure 1A). However, based on the cystic component, the tumor was also suspected to be a cystadenocarcinoma. The right portal vein was not visible on portography, but CT during arterial portography (CTAP) revealed defective portal perfusion in the whole right lobe of the liver (Figure 1C). This finding was suggestive of PVTT. Endoscopic retrograde cholangiography was performed to differentiate cystadenocarcinoma connected to a biliary duct. However, no specific findings of biliary carcinoma were noted and the collected bile sample was cytologically negative. For preoperative differential diagnosis of the tumor, echo-guided biopsy was performed. The biopsy revealed that the liver tumor was a liver metastasis from the colon cancer. With a preoperative diagnosis of liver metastasis from colon cancer, laparotomy was performed. Neither peritoneal dissemination nor hilar lymph node metastasis was detected. The liver tumor, measuring 28 × 25 mm in size, was located in segment 8, while PVTT was located in the right portal vein in direct communication with the liver tumor. Our patient underwent a right lobectomy (Figure 2A). The resected tumor, which had a fibrotic capsule, macroscopically resembled HCC. The cystic component observed on preoperative examination was not detected in the resected specimen. Histopathology of the resected liver tumor and PVTT revealed a moderately differentiated adenocarcinoma (Figure 2B). The histopathological findings from the resected tumor were similar to the previously resected ascending colon cancer. Based on the similarity, the final diagnosis for the liver tumor was a liver metastasis from the ascending colon cancer accompanied by macroscopic PVTT in the right portal branch. Histopathological infiltration into the endothelial layer of the portal vein was not seen. All resected margins were free from cancer. Postoperatively, our patient agreed to receive adjuvant chemotherapy. Our patient remains healthy, with no evidence of recurrence 51 months after the hepatectomy.
Figure 1

Computed tomography arteriography (CTA) of the liver tumor in the early phase (A) and the delayed phase (B). C) Computed tomography during arterial portography (CTAP) showing a portal vein tumor thrombus (arrow) and a perfusion defect in the entire right lobe.

Figure 2

A) Macroscopic view of the resected liver including the metastatic liver tumor (arrowheads) and the tumor thrombus in the right portal vein (arrows). Histopathological findings of the metastatic liver tumor (B) and primary colon cancer (C) showing moderately differentiated adenocarcinoma.

Computed tomography arteriography (CTA) of the liver tumor in the early phase (A) and the delayed phase (B). C) Computed tomography during arterial portography (CTAP) showing a portal vein tumor thrombus (arrow) and a perfusion defect in the entire right lobe. A) Macroscopic view of the resected liver including the metastatic liver tumor (arrowheads) and the tumor thrombus in the right portal vein (arrows). Histopathological findings of the metastatic liver tumor (B) and primary colon cancer (C) showing moderately differentiated adenocarcinoma.

Discussion

Microscopic tumor invasion into the intra-hepatic portal vein is detected in about 20% of cases with liver metastasis from colorectal cancer [4]. However, our review of previously reported cases revealed few instances of PVTT in the main portal branch [8-14]. In fact, the reported incidence of macroscopic PVTT similar to that observed in our case report is 2.8% (4 of 142) [9]. From January 1990 to December 2008, 231 patients underwent resection of liver metastases from primary colorectal cancer in our hospital. Of these patients, only our patient's case showed macroscopic PVTT (0.4%). Macroscopic examination of the resected tumor in our patient did not show the preoperatively detected cystic component of the tumor. It is possible that necrotic fluid, having filled the cystic component, was absorbed and thus replaced by the tumor before removal. The resected liver tumor and PVTT macroscopically resembled HCC, which commonly develops tumor thrombi and expansive growth in the portal vein and in the hepatic vein [17]. The capsule formation of HCC is possibly the result of mechanical compression or high inner pressure from the expansive tumor growth, thus it is also feasible that tumor thrombi might extend into the portal vein via a pressure gradient mechanism [18]. In contrast, liver metastases from colorectal cancer are generally less commonly surrounded by a capsule compared to HCC, with one study detecting encapsulated liver metastases from colorectal cancer in only 20% of cases [19]. The resected tumor in our patient, which was encapsulated, also resembled HCC in this point of the capsule formation. This resemblance to HCC may suggest that the PVTT in this case might have also expanded into the portal vein through a pressure gradient mechanism, as in HCC. Table 1 summarizes 15 reported cases of liver metastasis from colorectal cancer with macroscopic PVTT, including our patient. No specific clinical features typified patients with colorectal liver metastasis and PVTT with respect to age, gender, or the primary tumor site. With regard to the stage of the primary colorectal cancer, all the primary colorectal lesions recorded were divided into T3 or T4 according to the TNM classification [15], and lymph node metastasis was found in most of the cases (12 of 14, 86%). In 12 of the 15 cases (80%), liver metastasis was accompanied by PVTT, and the liver tumor was relatively large (60 ± 37 mm; range, 25 to 145 mm). PVTT was found metachronously in 12 patients, and synchronously with the primary tumor in the remaining three patients. Although Matsumoto et al. [14] suggested that survival after the operation of PVTT from colorectal cancer might depend on whether the PVTT had developed synchronously or metachronously, this suggestion seems not to be applied to the review in the present study. With regards to the liver tumor, anatomical liver resection was performed in all 15 patients. The one-year, three-year and five-year overall survival rates in the 15 cases after operation for PVTT were 64.3%, 51.4%, and 51.4%, respectively. Since this analysis was performed only in a limited number of patients, specifically successful cases, the analysis did not allow a precise general prognosis to be determined for metastatic liver tumor with PVTT. However, even if the aforementioned success bias was taken into consideration, this outcome seems to be relatively good. In general, anatomical liver resection is not usually employed for colorectal liver metastasis in contrast to HCC [20-22]. However, considering that colorectal liver metastasis with PVTT is likely to spread along the portal tributaries as in HCC, it may be speculated that anatomical liver resection, which is suitable for such liver metastasis, contributes to the favorable prognosis for colorectal liver metastasis with PVTT, as suggested by some investigators [9,10,14]. Today, some treatment options for colorectal liver metastasis have been established including surgery, ablation therapy, hepatic arterial infusion chemotherapy, and systemic chemotherapy, but there is no consensus for the treatment for colorectal liver metastasis accompanying PVTT. This successful case is not enough to conclude that surgery is the best treatment option for such liver metastasis, but we suggest at least that macroscopic PVTT is not a contraindication to liver surgery.

Conclusion

Our patient had a successfully resected liver metastasis from colorectal cancer with macroscopic PVTT. The prognosis of patients with such PVTT remains unclear, but from previous reports it would appear a better prognosis can be expected if the tumor is successfully resected by anatomical liver resection.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

YT researched the case, reviewed the literature, and was a major contributor to preparation of the manuscript. YS was responsible for the research and review. TY, KG, SN, HE, IM, and MO supported the preparation of the manuscript. HO, MY, OI, and SI prepared the final version of the manuscript. All the authors read and approved the final manuscript.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
  21 in total

1.  Hepatic resection for colorectal metastasis with macroscopic tumor thrombus in the portal vein.

Authors:  Keiichiro Tada; Norihiro Kokudo; Makoto Seki; Masashi Ueno; Kaoru Azekura; Hirotoshi Ohta; Toshiharu Yamaguchi; Toshiki Matusbara; Takashi Takahashi; Toshifusa Nakajima; Akio Yanagisawa; Tetsuichiro Muto
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

2.  [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver ].

Authors:  C COUINAUD
Journal:  Presse Med       Date:  1954-05-05       Impact factor: 1.228

3.  Portal vein tumor thrombus in colorectal liver metastasis.

Authors:  Kit Fai Lee; Wa Chu; Paul Bo San Lai
Journal:  Am J Surg       Date:  2005-09       Impact factor: 2.565

4.  Ultrasonically guided subsegmentectomy.

Authors:  M Makuuchi; H Hasegawa; S Yamazaki
Journal:  Surg Gynecol Obstet       Date:  1985-10

5.  The capsule surrounding primary liver tumors: wherefrom its prognostic significance?

Authors:  W F Grigioni; A D'Errico; G Biagini; A Mazziotti; L Bolondi; L A Liotta; A M Mancini; S Garbisa
Journal:  Int J Cancer       Date:  1990-04-15       Impact factor: 7.396

6.  Treatment of colorectal liver metastasis with biliary and portal vein tumor thrombi by hepatopancreatoduodenectomy.

Authors:  Teiichi Sugiura; Masato Nagino; Tomoki Ebata; Toshiyuki Arai; Koji Oda; Norihiro Yuasa; Yuji Nimura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2006

7.  Tumor thrombi in the portal vein system originating from gastrointestinal tract cancer.

Authors:  Akira Tanaka; Ryoji Takeda; Sumio Mukaihara; Katsumi Hayakawa; Koushou Takasu; Hiroaki Terajima; Yoshio Yamaoka; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

8.  Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years.

Authors:  T Nakashima; K Okuda; M Kojiro; A Jimi; R Yamaguchi; K Sakamoto; T Ikari
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

9.  Macroscopic portal vein tumor thrombi of liver metastasis from colorectal cancer.

Authors:  Takuichi Oikawa; Tadatoshi Takayama; Shunji Okada; Tomohisa Kamo; Masahiko Sugitani; Michiie Sakamoto
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-12-16

10.  Liver metastases with massive portal venous tumor thrombi from colorectal cancer: can be treated by surgical resection?

Authors:  Taizen Urahashi; Masakazu Yamamoto; Takehito Ohtsubo; Hideo Katsuragawa; Satoshi Katagiri; Ken Takasaki
Journal:  Hepatogastroenterology       Date:  2007 Jan-Feb
View more
  4 in total

1.  Chemotherapy for liver metastasis originating from colorectal cancer with portal vein tumor thrombosis: a case report.

Authors:  Atsushi Kawasaki; Kenji Mimatsu; Takatsugu Oida; Hisao Kano; Youichi Kuboi; Nobutada Fukino; Kazutoshi Kida; Sadao Amano
Journal:  Case Rep Oncol       Date:  2013-05-18

2.  Clinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis.

Authors:  I-Ming Kuo; Song-Fong Huang; Jy-Ming Chiang; Chien-Yuh Yeh; Kun-Ming Chan; Jinn-Shiun Chen; Ming-Chin Yu
Journal:  World J Surg Oncol       Date:  2015-03-04       Impact factor: 2.754

3.  Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide.

Authors:  Liming Cui; Bo Gao; Zhigang Cao; Xiaoying Chen; Shide Zhang; Weizhe Zhang
Journal:  Mol Med Rep       Date:  2016-01-12       Impact factor: 2.952

4.  Interleukin-12 prevents colorectal cancer liver metastases in mice.

Authors:  Fei Shen; Jiang-Lin Li; Weng-Song Cai; Guang-Hui Zhu; Wei-Li Gu; Lin Jia; Bo Xu
Journal:  Onco Targets Ther       Date:  2013-05-13       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.